Pharmicell Co: Operating and net income surged in H1 2025 despite lower revenue, led by Bio-Chemical sales

About this update from Pharmicell Co., Ltd

Revenue declined year-over-year, but operating and net income rose sharply in H1 2025, driven by the Bio-Chemical segment. Major R&D and plant investments continue, with strong cash reserves and new supply contracts supporting future growth.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Pharmicell Co., Ltd